Recent court decisions could make it more difficult for scientists to individually secure usage rights for research involving the study of human biological materials, as patients and clinicians have begun to question exactly what is granted—and to whom it is granted—when a patient signs an informed consent agreement.
Read the complete article by clicking on the link below.
Related Insights
25 October 2024
New 2025 SEC Examination Priorities: What Should a Private Fund Adviser Know?
On October 21, 2024, the Division of Examinations (the “Division”) of the U.S. Securities and Exchange Commission (the “SEC”) announced its annual 2025 examination priorities (the “Examination Priorities”)
09 December 2024
Events
Milwaukee CLE Week 2024
We are excited to announce Foley's Annual Milwaukee CLE Week! This year's program will feature three days of in-person sessions, focusing on essential business, industry, and ethics topics.
23 October 2024
Health Care Law Today
Private Equity Investments in Oncology: Top Five Things to Know
Although private equity (PE) sponsors have been active investors in the health care services industry for the last decade, PE-backed health care providers today constitute only 4% of the United States health market by revenue.